Evgen Pharma (EVG): Encouraging interim data from the STEM trial
Evgen (EVG) is a virtual pharmaceutical company focused on the development of asynthetic version of a natural product, sulforaphane, which is known to modulate
key signalling pathways involved in cellular protection and inflammation. EVG has
created new and stable variants of sulforaphane using its proprietary technology,
Sulforadex, enabling it to be used as a therapeutic for the first time. SFX-01 is
currently in Phase II trials for both subarachnoid haemorrhage (SAH) and ER+
breast cancer, with read-outs expected around the end of 2018. Meanwhile, EVG
has disclosed positive interim data from its STEM trial in metastatic breast cancer.
Evgen Pharma is a clinical stage drug development company. Co.'s pipeline is based on its proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.